Parkin, Proteintech, 14060-1-AP

Our team has carried out deep research in the published scientific literature to identify papers and reports using antibodies directed against human E3 ubiquitin-protein ligase parkin and followed up by extraction and evaluation of the available data to assess its performance according to pAbmAbs rating criteria.

YCharOS is here conducting a large head-to-head study comparing 16 commercial research antibodies against human E3 ubiquitin-protein ligase parkin encoded by PRKN.

The collection of antibodies was tested using SH-SY5Y WT and PRKN KO cells in the applications WB (WT and KO cell lysates/50 µg protein), IP (WT cell lysate) and IF (WT and KO cells) according to YCharOS standard protocols (see reference).

In WB (1:1000 ab dilution) 14060-1-AP detected multiple bands none of which were specific to WT cell lysate. Only antibodies that depleted the antigen from the cell lysate were used for IP; this antibody did not deplete the antigen. In IF (1:800 ab dilution), comparable staining intensity were observed in both WT and KO cells.

We highly encourage other scientists to share their observations.